Repositioning leptin as a therapy for Alzheimer's disease

Therapy

Volumn 8, Issue 5, 2011, Pages 481-490

  Johnston, Jane M ^a   Greco, Steven J ^a   Hamzelou, Ashkan ^a   Ashford, J Wesson ^b   Tezapsidis, Nikolaos ^a  

^a Neurotez Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; cognition; leptin; neurodevelopment; neurons

Indexed keywords

AMYLIN DERIVATIVE; AMYLOID BETA PROTEIN; ANTIOBESITY AGENT; ANTIVIRUS AGENT; LEPTIN; LEPTIN RECEPTOR; PEGYLATED RECOMBINANT NATIVE HUMAN LEPTIN; PLACEBO; PRAMLINTIDE; RECOMBINANT LEPTIN; RECOMBINANT METHIONYL HUMAN LEPTIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMENORRHEA; BIOLOGICAL THERAPY; BRAIN CORTEX; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HIPPOCAMPUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LIPODYSTROPHY; LONG TERM CARE; LOW DRUG DOSE; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; SUBSTITUTION THERAPY;

EID: 80053998975     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.57     Document Type: Review

References (93)

1. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994). (Pubitemid 24365442)
2. Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin. Pharmacokinet. 47(11), 753-764 (2008).
3. Tartaglia LA. The leptin receptor. J. Biol. Chem. 272, 6093-6096 (1997). (Pubitemid 27118072)
4. Caron E, Sachot C, Prevot V et al. Distribution of leptin-sensitive cells in the postnatal and adult mouse brain. J. Comp. Neurol. 518, 459-476 (2010).
5. Friedman JM. Leptin, leptin receptors and the control of body weight. Nutr. Rev. 56(2), 38-46 (1998).
6. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395(6704), 763-770 (1998). (Pubitemid 28485436)
7. Harris RB, Zhou J, Redmann SM Jr et al. A leptin dose study in obese (ob/ob) and lean (+/?) mice. Endocrinology 139(1), 8-19 (1998). (Pubitemid 28166285)
8. Dardeno TA, Chou SH, Moon HS et al. Leptin in human physiology and therapeutics. Front. Neuroendocrinol. 31, 377-393 (2010).
9. Udagawa J, Hashimoto R, Suzuki H et al. The role of leptin in the development of the cerebral cortex in mouse embryos. Endocrinology 147, 647-658 (2006). (Pubitemid 43112978)
10. Bouret SG. Neurodevelopmental actions of leptin. Brain Res. 1350, 2-9 (2010).
11. Bereiter D, Jeanrenaud B. Altered neuroanatomical organization in the central nervous system of the genetically obese (ob/ob) mouse. Brain Res. 165, 249-260 (1979). (Pubitemid 9153505)
12. Ahima RS, Bjorbaek C, Osei S et al. Regulation of neuronal and glial proteins by leptin: implications for brain development. Endocrinology 140, 2755-2762 (1999). (Pubitemid 32245155)
13. Steppan CM, Swick AG. A role for leptin in brain development. Biochem. Biophys. Res. Commun. 256, 600-602 (1999). (Pubitemid 29301152)
14. O'Malley D, MacDonald N, Mizielinska S et al. Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol. Cell Neurosci. 35(4), 559-572 (2007). (Pubitemid 47193112)
15. Fewlass DC, Noboa K, Pi-Sunyer FX et al. Obesity-related leptin regulates Alzheimer's Ab. FASEB J. 18(15), 1870-1878 (2004).
16. Greco SJ, Sarkar S, Johnston JM et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem. Biophys. Res. Comm. 376(3), 536-541 (2008).
17. Greco SJ, Bryan KJ, Sarkar S et al. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 19(4), 1155-1167 (2010).
18. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 132, 645-660 (2008). (Pubitemid 351253687)
19. Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282(16), 1568-1575 (1999). (Pubitemid 29504050)
20. Belgardt BF, Bruning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann. NY Acad. Sci. 1212, 97-113 (2010).
21. Banks WA, Coon AB, Robinson SM et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53(5), 1253-1260 (2004). (Pubitemid 38569011)
22. Banks WA. The blood-brain barrier as a cause of obesity. Curr. Pharm. Des. 14(16), 1606-1614 (2008). (Pubitemid 352002988)
23. Fujioka K, Patane J, Lubina J et al. CSF leptin levels after exogeneous administration of recombinant methionyl human leptin. JAMA 282(16), 1517-1518 (1999). (Pubitemid 29504043)
24. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110(8), 1093-1103 (2002). (Pubitemid 35215890)
25. Galgani JE, Greenway FL, Caglayan S et al. Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin deficient patients J. Clin. Endocrinol. Metab. 95(2), 851-855 (2010).
26. Heymsfield SB, Fong TM, Gantz I et al. Fat and energy partitioning: longitudinal observations in leptin-treated adults homozygous for a lep mutation. Obesity 14(2), 258-265 (2006). (Pubitemid 46214756)
27. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. Natl Acad. Sci. USA 101(13), 4531-4536 (2004). (Pubitemid 38437445)
28. Licinio J, Milane M, Thakur S et al. Effects of leptin on intake of specific micro-and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. Appetite 49(3), 594-599 (2007). (Pubitemid 350030335)
29. Paz-Filho G, Esposito K, Hurwitz B et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am. J. Physiol. Endocrinol. Metab. 295(6), E1401-E1408 (2008).
30. Paz-Filho GJ, Babikian T, Asarnow R et al. Leptin replacement improves cognitive development. PLoS One 3(8), e3098 (2008).
31. Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obes. Rev. 12(501), e315-e323 (2011).
32. Zelissen PM, Stenlof K, Lean ME et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabet. Obes. Metab. 7(6), 755-761 (2005). (Pubitemid 41601081)
33. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. 85(11), 4003-4009 (2000). (Pubitemid 32055343)
34. Hukshorn CJ, van Dielen FM, Buurman WA et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int. J. Obes. Relat. Metab. Disord. 26(4), 504-509 (2002). (Pubitemid 34407263)
35. Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am. J. Clin. Nutr. 77(4), 771-776 (2003).
36. Hukshorn CJ, Menheere PP, Westerterp-Plantenga MS et al. The effect of pegylated human recombinant leptin (PEG-OB) on neuroendocrine adaptations to semi-starvation in overweight men. Eur. J. Endocrinol. 148(6), 649-655 (2003). (Pubitemid 36758295)
37. Chan JL, Roth JD, Weyer C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J. Investig. Med. 57(7), 777-783 (2009).
38. Moon HS, Chamberland JP, Diakopoulos KN et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathway in peripheral tissues: in vitro and ex vivo studies in humans. Diabet. Care 34, 132-138 (2011).
39. Ravussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlinitide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17(9), 1736-1743 (2009).
40. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored byamylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105(20) 7257-7262 (2008). (Pubitemid 351754465)
41. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346(8), 570-578 (2002). (Pubitemid 34438818)
42. Oral EA, Ruiz E, Andewelt A et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J. Clin. Endocrinol. Metab. 87(7), 3110-3117 (2002). (Pubitemid 34816352)
43. Oral EA, Chan JL. Rational for leptin-replacement therapy for severe lipodystrophy. Endocr. Pract. 6(2), 324-333 (2010).
44. Musso C, Cochran E, Javor E et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism 54(2), 255-263 (2005). (Pubitemid 40174856)
45. Brennan AM, Lee JH, Tsiodras S et al. r-metHuleptin improves highly active antiretroviral therapy-induces lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur. J. Endocrinol. 160(2), 173-176 (2009).
46. Lee JH, Chan JL, Sourlas E et al. recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91(7), 2605-2611 (2006). (Pubitemid 44024625)
47. Mulligan K, Khatami H, Schwarz JM et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J. Clin. Endocrinol. Metab. 94(4), 1137-1144 (2009).
48. Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome. J. Clin. Endocrinol. Metab. 94(4), 1089-1091 (2009).
49. Matochik JA, London ED, Yildiz BO et al. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J. Clin. Endocrinol. Metab. 90(5), 2851-2854 (2005). (Pubitemid 40686335)
50. Pannacciulli N, Le DS, Chen K et al. Relationships between plasma leptin concentrations and human brain structure: a voxel-based morphometric study. Neurosci. Lett. 412(3), 248-253 (2007). (Pubitemid 46109158)
51. Lazarov O, Mattson MP, Peterson DA et al. When neurogenesis encounters aging and disease. Trends Neurosci. 33(12), 569-579 (2010).
52. Garza JC, Guo M, Zhang W et al. Leptin increases adult hippocampal neurogenesis in vivo and in vitro. J. Biol. Chem. 283, 18238-18247 (2008).
53. Farr SA, Banks WA, Morley JE. Effects of leptin on memory processing. Peptides 27, 1420-1425 (2006). (Pubitemid 43767004)
54. Guo Z, Jiang H, Xu X et al. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J. Biol. Chem. 283(3), 1754-1763 (2008).
55. Garcia-Caceres C, Fuente-Martin E, Burgos-Ramos E et al. Differential acute and chronic effects of leptin on hypothalamic astrocyte morphology and synaptic protein levels. Endocrinology 152, 1809-1818 (2011).
56. Udagawa J, Nimura M, Otani H. Leptin affects oligodendroglial development in the mouse embryonic cerebral cortex. Neuro. Endocrinol. Lett. 27(1-2), 177-182 (2006). (Pubitemid 43970790)
57. Paz-Filho G, Wong ML, Licinio J. The procognitive effects of leptin in the brain and their clinical implications. Int. J. Clin. Pract. 64(13), 1808-1812 (2010).
58. Huang JS, Letendre S, Marquie-Beck J et al. Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. J. Neuroimmu. Pharmacol. 2(4), 352-358 (2007).
59. Alberici A, Boccio L, Geroldi C et al. Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. J. Neurol. Neurosurg. Psychiat. 79(6), 712-715 (2008). (Pubitemid 351829447)
60. Calandra C, Musso F, Musso R. The role of leptin in the etiopathogenesis of anorexia nervosa and bulimia. Eat. Weight Disord. 8(2), 130-137 (2003).
61. Eckert ED, Pomeroy C, Raymond N et al. Leptin in anorexia nervosa. J. Clin. Endocrinol. Metab. 83(3), 791-795 (1998). (Pubitemid 28496448)
62. Westling S, Ahrén B, Träskman-Bendz L et al. Low CSF leptin in female suicide attempters with major depression. J. Affect. Disord. 81(1), 41-48 (2004). (Pubitemid 38759325)
63. Blardi P, de Lalla A, Ceccatelli L et al. Variations of plasma leptin and adiponectin levels in autistic patients. Neurosci. Lett. 479(1), 54-57 (2010).
64. Lorefalt B, Toss G, Granerus AK. Weight loss, body fat mass and leptin in Parkinson's disease. Movement Disord. 24, 885-890 (2009).
65. Fiszer U, Michalowska M, Baranowska B et al. Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol. Scand. 121, 230-236 (2010).
66. Narita K, Kosaka H, Okazawa H et al. Relationship between plasma leptin level and brain structure in elderly: a voxel-based morphometric study. Biol. Psychiat. 65(11), 992-994 (2009).
67. + progenitor cells in Alzheimer's disease. PLoS ONE 6(5), e20286 (2011).
68. Power DA, Noel J, Collins R et al. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement. Geriatr. Cogn. Disord. 12, 167-170 (2001). (Pubitemid 32149724)
69. Holden KF, Lindquist K, Tylavsky FA et al. Serum leptin level and cognition in the elderly: findings from the Health ABC study. Neurobiol. Aging 30(9), 1483-1489 (2009).
70. Lieb W, Beiser AS, Vasan RS et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302(23), 2565-2572 (2009).
71. Merlo S, Spampinato S, Canonico PL et al. Alzheimer's disease: brain expression of a metabolic disorder? Trends Endocrinol. Metab. 21(9), 537-544 (2010).
72. Tezapsidis N, Johnston JM, Smith MA et al. Leptin: a novel therapeutic strategy for Alzheimer's disease. J. Alzheimers Dis. 16(4), 731-740 (2009).
73. Ashford JW, Soultanian NS, Zhang SX et al. Neuropil threads are collinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. J. Neuropathol. Exp. Neurol. 57(10), 972-978 (1998). (Pubitemid 28478007)
74. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD neuropathology. Neurobiol. Aging 25(5), 641-650 (2004). (Pubitemid 38686487)
75. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977-1981(1993). (Pubitemid 23069980)
76. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6, 345-351 (2003).
77. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur. J. Pharmacol. 585(1), 119-129 (2008).
78. Ott A, Stolk RP, van Harskamp F. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53, 1937-1942 (1999).
79. Mazzali G, Bissoli L, Gambina S et al. Energy balance in Alzheimer's disease. J. Nutr. Health Aging 6, 247-253 (2002).
80. Greco SJ, Sarkar S, Johnston JM et al. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Comm. 380(1), 98-104 (2009).
81. Dagon Y, Avraham Y, Magen I et al. Nutritional status, cognition, and survival: a new role for leptin and AMP kinase. J. Biol. Chem. 280(51), 42142-42148 (2005). (Pubitemid 43023183)
82. Ebihara K, Kusakabe T, Hirata M et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92(2), 532-541 (2007).
83. Mackintosh RM, Hirsch J. The effects of leptin administration in non-obese human subjects. Obes. Res. 9(8), 462-469 (2001). (Pubitemid 33600290)
84. Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J. Mol. Neurosci. 23, 157-165 (2004). (Pubitemid 41389382)
85. Roses AD, Lutz MW, Amrine-Madsen H et al. TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 10(5), 375-384 (2010).
86. Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med. 351(10), 987-997 (2004). (Pubitemid 39166262)
87. Kendall BJ, Macdonald GA, Hayward NK et al. Leptin and the risk of Barrett's oesophagus. Gut 57(4), 448-454 (2008).
88. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr. Relat. Cancer 16(4), 1197-1210 (2009).
89. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 10, 187-198 (2011).
90. Andrico S, Gambera A, Specchia C et al. Leptin in functional hypothalamic amenorrhoea. Hum. Reprod. 17(8), 2043-2048 (2002).
91. McDuffie JR, Riggs PA, Calis KA et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J. Clin. Endocrinol. Metab. 89(9), 4258-4263 (2004). (Pubitemid 39244422)
92. Baicy K, London ED, Monterosso J et al. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc. Natl Acad. Sci. USA 104(46), 18276-18279 (2007). (Pubitemid 350210857)
93. Rosenbaum M, Sy M, Pavlovich K et al. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J. Clin. Invest. 118(7), 2583-2591 (2008). (Pubitemid 351949785)